New drug cocktail targets rare liver cancer in 29-Patient trial

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. About 29 participants will receive the treatment to see if it shrinks tumors and improves survival. The goal is to find a better option for this hard-to-treat cancer.